Primary thrombocythemia: new drugs for an evolving disease.
Balduini
C L
CL
D000368:Aged; D000477:Alkylating Agents / Q000627:therapeutic use; D005260:Female; D006474:Hemorrhagic Disorders / Q000453:epidemiology / Q000209:etiology; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000627:therapeutic use; D007155:Immunologic Factors / Q000627:therapeutic use; D015994:Incidence; D016898:Interferon-alpha / Q000627:therapeutic use; D007938:Leukemia / Q000139:chemically induced; D008875:Middle Aged; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D010983:Plateletpheresis; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000188:drug therapy; D011379:Prognosis; D011799:Quinazolines / Q000627:therapeutic use; D012074:Remission Induction; D012306:Risk; D013920:Thrombocythemia, Essential / Q000150:complications / Q000188:drug therapy* / Q000401:mortality / Q000628:therapy; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology
D000477:Alkylating Agents; D007155:Immunologic Factors; D016898:Interferon-alpha; D010761:Phosphorus Radioisotopes; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide; D006918:Hydroxyurea